1,3-dibromo-5-{(1'-hydroxy-1'-methyl)ethyl}benzene | 234430-04-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1,3-dibromo-5-{(1'-hydroxy-1'-methyl)ethyl}benzene
• 英文别名: 1,3-dibromo-5-{(1-hydroxy-1-methyl)ethyl}benzene；2-(3,5-dibromophenyl)propan-2-ol；2-(3,5-Dibromophenyl)propan-2-ol
• CAS: 234430-04-7
• 化学式: C₉H₁₀Br₂O
• 分子量: 293.986
• InChiKey: GLVDYTATHPJIIZ-UHFFFAOYSA-N

物化性质

• 沸点：
  294.1±25.0 °C(Predicted)
• 密度：
  1.734±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1,3-dibromo-5-{(1'-hydroxy-1'-methyl)ethyl}benzene 在 aluminum (III) chloride 、 正丁基锂 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  Design, synthesis and in vivo anti-hyperglycemic activity of gem-dimethyl-bearing C-glucosides as SGLT2 inhibitors

  摘要：

  A series of gem-dimethyl-bearing C-glucosides were designed and synthesized as SGLT2 inhibitors, with anhydrous aluminum chloride-mediated Friedel-Crafts alkylation to construct the gem-dimethyl functionality being the key step. The in vivo anti-hyperglycemic activity was evaluated with mice oral glucose tolerance test (OGTT), and all the synthesized compounds showed significant but less potent anti-hyperglycemic activity than the positive control dapagliflozin. (C) 2011 Gui Long Zhao. Published by Elsevier B.V. on behalf of Chinese Chemical Society. All rights reserved.

  DOI：

  10.1016/j.cclet.2011.05.022
• 作为产物：
  描述：

  3,5-二溴苯甲酸 在 硫酸 作用下， 以 四氢呋喃 、 苯 为溶剂， 生成 1,3-dibromo-5-{(1'-hydroxy-1'-methyl)ethyl}benzene
  参考文献：
  名称：

  Design, synthesis and in vivo anti-hyperglycemic activity of gem-dimethyl-bearing C-glucosides as SGLT2 inhibitors

  摘要：

  A series of gem-dimethyl-bearing C-glucosides were designed and synthesized as SGLT2 inhibitors, with anhydrous aluminum chloride-mediated Friedel-Crafts alkylation to construct the gem-dimethyl functionality being the key step. The in vivo anti-hyperglycemic activity was evaluated with mice oral glucose tolerance test (OGTT), and all the synthesized compounds showed significant but less potent anti-hyperglycemic activity than the positive control dapagliflozin. (C) 2011 Gui Long Zhao. Published by Elsevier B.V. on behalf of Chinese Chemical Society. All rights reserved.

  DOI：

  10.1016/j.cclet.2011.05.022

文献信息

• Field-Induced Ferrimagnetic State in a Molecule-Based Magnet Consisting of a Co^II Ion and a Chiral Triplet Bis(nitroxide) Radical
  作者：Youhei Numata、Katsuya Inoue、Nikolai Baranov、Mohamedally Kurmoo、Koichi Kikuchi

  DOI：10.1021/ja064828i

  日期：2007.8.1

  one-dimensional chains that are packed parallel to each other in the noncentrosymmetric P1 space group. 1 exhibits four magnetic ground states: paramagnetic; antiferromagnetic; forced ferrimagnetic; field-induced metastable ferrimagnetic. In the paramagnetic state (T > 20 K), it presents short-range antiferromagnetic interaction between Co ion and nitroxide radical and has a minimum of chimT value at 220 K. The

  我们介绍了一种新的基于分子的磁体 [Co(hfac)2].BNO* (1)，其中 hfac = 1,1,1,5，的磁特性的合成、晶体结构以及温度和场依赖性， 5,5-六氟乙酰丙酮和 BNO* 是手性三联体双（硝基氧化物），1,3-双（N-叔丁基-N-氧基氨基）-5-1'-甲基-1'-[2''- (S)-甲基丁氧基]乙基}苯。对映异构体纯 BNO 的存在诱导手性一维链的形成，这些链在非中心对称 P1 空间群中相互平行排列。1 表现出四种磁性基态：顺磁性；反铁磁性；强制亚铁磁性；场致亚稳态亚铁磁体。在顺磁性状态下（T > 20 K），它呈现出 Co 离子和氮氧自由基之间的短程反铁磁相互作用，并且在 220 K 时具有最小的 chimT 值。发现在 220-300 K 温度范围内估计的 Weiss 温度为 -89.9 K。在 20 K (TN) 处，建立了反铁磁长程排序。在 4 K < T <
• [EN] BETA AMINO ACID DERIVATIVES AS INTEGRIN ANTAGONISTS<br/>[FR] DÉRIVÉS D'ACIDES BÊTA AMINÉS EN TANT QU'ANTAGONISTES D'INTÉGRINE
  申请人：UNIV SAINT LOUIS

  公开号：WO2014015054A1

  公开（公告）日：2014-01-23

  Disclosed herein are novel pharmaceutical agents which are useful as integrin receptor antagonists that mediate the pathologic processes of angiogenesis and fibrosis and as such are useful in pharmaceutical compositions and in methods for treating conditions mediated by these integrins by inhibiting or antagonizing these integrins. The novel pharmaceutical agents include those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods and intermediates useful for making the pharmaceutical agents and methods of using the pharmaceutical agents are also provided.

  本发明公开了新型的药物制剂，这些药物制剂作为整合素受体的拮抗剂，能够介导血管生成和纤维化的病理过程，因此可用于药物组合物中，以及在通过抑制或拮抗这些整合素来治疗由这些整合素介导的疾病的方法中。这些新型的药物制剂包括以下公式的那些：其中变量定义如下。还提供了包含此类药物制剂的药物组合物、试剂盒和制造品。此外，还提供了用于制造药物制剂的方法和中间体，以及使用药物制剂的方法。
• Beta Amino Acid Derivatives as Integrin Antagonists
  申请人：Saint Louis University

  公开号：US20140038910A1

  公开（公告）日：2014-02-06

  Disclosed herein are novel pharmaceutical agents which are useful as integrin receptor antagonists that mediate the pathologic processes of angiogenesis and fibrosis and as such are useful in pharmaceutical compositions and in methods for treating conditions mediated by these integrins by inhibiting or antagonizing these integrins. The novel pharmaceutical agents include those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods and intermediates useful for making the pharmaceutical agents and methods of using the pharmaceutical agents are also provided.

  本文揭示了一种新型药物，它们可用作整合素受体拮抗剂，介导血管生成和纤维化的病理过程，并且因此可用于制备药物组合物和治疗通过抑制或拮抗这些整合素介导的疾病的方法。这些新型药物包括以下公式中的药物：其中变量在此定义。还提供了包含这些药物的制药组合物、试剂盒和制品。还提供了用于制造药物的方法和中间体以及使用药物的方法。
• A Chiral Molecular Based Metamagnet Prepared from Manganese Ions and a Chiral Triplet Organic Radical as a Bridging Ligand
  作者：Hitoshi Kumagai、Katsuya Inoue

  DOI：10.1002/(sici)1521-3773(19990601)38:11<1601::aid-anie1601>3.0.co;2-#

  日期：1999.6

  Below 5.4 K the one-dimensional polymeric complex made up of manganese(II) hexafluoroacetylacetonate units and bridging bisaminooxylbenzene diradicals (shown in the picture) behaves as a metamagnet. The R-helical chain not only contains an S-configured chiral carbon center, but also an R-configured C2 -symmetric chiral skeleton of the organic ligand.
• BETA AMINO ACID DERIVATIVES AS INTEGRIN ANTAGONISTS
  申请人：Saint Louis University

  公开号：EP2875021A1

  公开（公告）日：2015-05-27